In the TNM (Tumor, Node, Metastasis) classification and staging of breast cancer, what is the incorrect statement regarding fibroadenoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The incorrect statement regarding fibroadenoma in the TNM classification and staging of breast cancer is that fibroadenomas are premalignant lesions. Fibroadenomas are benign breast lesions and are not included in the TNM classification system, which is specifically designed for malignant tumors. The TNM system categorizes cancerous breast tumors based on the size of the primary tumor (T), involvement of regional lymph nodes (N), and presence of distant metastasis (M) 1. Since fibroadenomas are benign proliferations of breast tissue composed of stromal and epithelial elements, they do not have malignant potential that requires staging. They are typically managed conservatively with observation or surgical excision if symptomatic or concerning, but they do not undergo cancer staging 1. This distinction is important for clinicians to understand when evaluating breast masses, as the management approach differs significantly between benign lesions like fibroadenomas and malignant breast cancers that require TNM staging. Some key characteristics of fibroadenomas include:

  • Mostly benign
  • Mostly mobile
  • Diagnosis can be suggested by mammogram, but definitive diagnosis often requires biopsy
  • May be huge in size However, the statement that fibroadenomas are premalignant lesions is incorrect, as they are generally considered to have very low to no malignant potential 1.

From the Research

Incorrect Statement Regarding Fibroadenoma

The incorrect statement regarding fibroadenoma in the context of TNM classification and staging of breast cancer is:

  • Premalignant lesion: Fibroadenomas are mostly benign and not considered premalignant lesions 2, 3, 4, 5, 6.

Characteristics of Fibroadenoma

Fibroadenomas are characterized by the following:

  • Mostly benign: Fibroadenomas are common benign breast lesions, especially in premenopausal women 2.
  • Mostly mobile: Fibroadenomas are usually mobile and present as small, painless lumps 3.
  • Diagnosis by mammogram: While mammography can be used to diagnose fibroadenomas, the diagnosis is often based on a combination of clinical examination, imaging, and non-surgical tissue biopsy (the triple test) 2.
  • May be huge: Giant fibroadenomas can occur, although they are rare, and can grow to a large size 3, 5.

Importance of Accurate Diagnosis

It is essential to accurately diagnose fibroadenomas to distinguish them from malignant lesions, such as breast cancer 4, 6. A thorough evaluation, including tissue sampling, is necessary to confirm the diagnosis and rule out malignancy 2, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fibroadenoma of the breast.

The Medical journal of Australia, 2001

Research

Breast cancer mimicking fibroadenomas in postmenopausal women.

International journal of surgery (London, England), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.